Short answer
Tango Therapeutics, Inc. (TNGX) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$55M.
Q2 2026 key financials · XBRL
- Revenue
- $0
- −100.0% YoY
- Net income
- −$55M
- −42.4% YoY · −21.6% QoQ
- EPS (diluted)
- −$0.36
- −2.9% YoY · −12.5% QoQ
Source: XBRL data from the Tango Therapeutics, Inc. (TNGX) Q2 2026 10-Q on SEC EDGAR. USD.
Tango Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes to 2025 Form 10-K risk factors, per June 30, 2026 10-Q
- Carried-forward business risk: additional unknown or currently immaterial risks could materially harm results
- No newly added regulatory, legal, compliance, operational, competitive, or financial risk identified this quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tango Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.